Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18386623 | 0.90 | CYP1A2 (0.41) | CYP1A2CYP2A6SIGMAR1HRH3 | |
| SCHEMBL16594922 | 0.89 | KDM4E (0.49) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL16594736 | 0.89 | KDM4E (0.49) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL4813306 | 0.89 | SIGMAR1 (0.59) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL2093292 | 0.87 | SIGMAR1 (0.57) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL2097303 | 0.85 | SIGMAR1 (0.56) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL8500204 | 0.85 | SIGMAR1 (0.56) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL869422 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL29546077 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A | |
| SCHEMBL2093537 | 0.81 | CYP1A2 (0.57) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0487714-A4 | SELECTIVE ETHYLATION OF NAPHTHALENE COMPOUNDS | — | 1993-07-07 | — | — | EP | claimed |
| EP-0487714-A1 | SELECTIVE ETHYLATION OF NAPHTHALENE COMPOUNDS | AMOCO CORPORATION (US) | 1992-06-03 | — | — | EP | claimed |
| WO-1992000260-A1 | SELECTIVE ETHYLATION OF NAPHTHALENE COMPOUNDS | AMOCO CORPORATION (US) | 1992-01-09 | — | — | WO | claimed |
| CN-119569545-A | Preparation method of methyl ether compound of fatty alcohol | 中国人民解放军军事科学院防化研究院 | 2025-03-07 | — | — | CN | disclosed |
| US-8524729-B2 | Cinnamoyl derivatives and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524729-B2 | Cinnamoyl derivatives and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20070123521-A1 | Cinnamoyl derivatives and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123521-A1 | Cinnamoyl derivatives and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0487714-A4 | SELECTIVE ETHYLATION OF NAPHTHALENE COMPOUNDS | — | 1993-07-07 | — | — | EP | disclosed |
| EP-0487714-A1 | SELECTIVE ETHYLATION OF NAPHTHALENE COMPOUNDS | AMOCO CORPORATION (US) | 1992-06-03 | — | — | EP | disclosed |
| WO-1992000260-A1 | SELECTIVE ETHYLATION OF NAPHTHALENE COMPOUNDS | AMOCO CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CYP1A2 1549/4885CYP2A6 1077/4885SIGMAR1 3155/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | CYP1A2 1764/4885CYP2A6 1760/4885SIGMAR1 3540/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CYP1A2 1549/4885CYP2A6 1077/4885SIGMAR1 3155/4885 |
| US-20070123521-A1 | Cinnamoyl derivatives and use thereof | CES2, EBP, CPT1A | CYP1A2 132/4885CYP2A6 367/4885SIGMAR1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.